Castle Biosciences Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
CSTL Nasdaq 2834 https://castlebiosciences.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Castle Biosciences Inc

We're Not Worried About Castle Biosciences' (NASDAQ:CSTL) Cash Burn - Apr 17th, 2024 11:06 am
Castle Biosciences to Release First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 2, 2024 - Apr 11th, 2024 11:00 am
Castle Biosciences Celebrates Esophageal Cancer Awareness Month through Advocacy and Educational Collaborations - Apr 10th, 2024 9:00 pm
Castle Biosciences’ Chief Financial Officer Frank Stokes Recognized as a Top CFO of Houston for Second Consecutive Year - Apr 10th, 2024 11:00 am
What Makes Castle Bioscience (CSTL) a Prospective Investment? - Apr 5th, 2024 8:43 am
Presentations at EADO Highlight Potential Impact of Castle Biosciences’ DecisionDx®-Melanoma and DecisionDx®-SCC Tests on the Management of Patients with Skin Cancer - Apr 4th, 2024 8:30 pm
Castle Biosciences to Present at the 23rd Annual Needham Virtual Healthcare Conference - Apr 2nd, 2024 11:00 am
Castle Biosciences Announces Updates to its Board of Directors - Mar 27th, 2024 9:00 pm
Castle Biosciences Earns a Top Workplaces USA Award for the Third Consecutive Year - Mar 25th, 2024 11:00 am
Long-term Outcomes Data Shared at SSO 2024 Show That Patients with a Low-Risk DecisionDx®-Melanoma Test Result Were Recurrence Free at Three Years, Including Those Who Utilized the Test to Help Guide the Decision to Avoid an SLNB - Mar 22nd, 2024 8:30 pm
Does Castle Bioscience (CSTL) Have Robust Growth Prospects? - Mar 20th, 2024 9:17 am
Leading Squamous Cell Carcinoma Practitioners Publish Consensus Guidelines Integrating DecisionDx®-SCC into a Clinical Workflow to Improve Decision-Making Regarding the Use of Adjuvant Radiation Therapy - Mar 19th, 2024 11:00 am
New Study Shows that the Drug-Drug Interactions and Lifestyle Factors Provided by Castle Biosciences’ IDgenetix® Test Significantly Improve Medication Recommendations Over Drug-Gene Interactions Alone for Patients 65 and Older - Mar 15th, 2024 8:30 pm
Castle Biosciences to Present at the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum - Mar 12th, 2024 11:00 am
Castle Biosciences to Present New Data Highlighting the Clinical Value of its Dermatologic Tests for Patients with Skin Cancer at the 2024 American Academy of Dermatology (AAD) Annual Meeting - Mar 8th, 2024 9:30 pm
In Novel Cohort, New Data Confirms DecisionDx®-SCC Provides Significant, Independent and Clinically Actionable Risk-Stratification of Patients, Including in Various High-Risk Subgroups - Mar 7th, 2024 12:00 pm
Castle Biosciences, Inc. (NASDAQ:CSTL) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates - Mar 2nd, 2024 12:49 pm
Castle Biosciences Full Year 2023 Earnings: Beats Expectations - Mar 1st, 2024 11:46 am
Castle Biosciences, Inc. (NASDAQ:CSTL): Are Analysts Optimistic? - Mar 1st, 2024 11:46 am
Castle Biosciences, Inc. (NASDAQ:CSTL) Q4 2023 Earnings Call Transcript - Feb 29th, 2024 3:37 pm